Endoxifen complements Atossa’s cancer focus
Atossa raised $2.875m in an equity raise in September 2016. We expect the proceeds to be allocated to Atossa’s two active pipeline programs: its 30-pt Phase II study on its intraductal microcatheter (IDMC) delivering fulvestrant to breast ducts in patients scheduled for mastectomy or lumpectomy, and its oral endoxifen candidate, expected to start human studies in 2017 as potential treatment for breast cancer patients refractory to tamoxifen. We obtain an rNPV-based equity valuation of $10.7m.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.